Develops bispecific T-cell receptor (TCR) therapies for cancer, led by approved treatment Kimmtrak for melanoma.
Develops bispecific T-cell receptor (TCR) therapies for cancer, led by approved treatment Kimmtrak for melanoma.
Earns most of its revenue from Kimmtrak, an infusion approved in 2022 for uveal melanoma (an eye cancer), but only for patients with a particular tissue type, which limits who can be treated. The rest of the pipeline, including drugs aimed at the PRAME cancer marker, is still in trials.
Moat: narrow (IP / patents, process know-how). Proprietary ImmTAC bispecific TCR platform behind the first approved TCR therapeutic, hard to replicate.
Headquarters: Oxfordshire, UK · Founded: 2008 · Employees: 524
Size Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh (IMCR) is a United States Health Care company (Biotechnology) with a market value of $1.44B, the 1995th largest of 3,085 United States companies the cockpit tracks. Shares closed at $27.51 on 18 Nov 2026.
Performance Over six months the shares fell 6.9%, against -20.3% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue grew 13.0% over the last twelve months (peer median +26.4%); the operating margin is -6.8% (peer median -295.1%).
Valuation It trades at 2.3× enterprise value to sales against a peer median of 26.5× (cheapest of 17).
Credit Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh has 1 bond outstanding ($402M).
Short interest Short interest is 15.1% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $429M | $401M | $310M | $250M | $177M |
| Revenue growth | — | +29% | +24% | +41% | — |
| Gross profit | $420M | $393M | $303M | $245M | $169M |
| EBITDA | -$25.1M | -$42.2M | -$66.3M | -$55.8M | -$56.4M |
| Net income | -$32.1M | -$35.6M | -$51.1M | -$55.5M | -$50.8M |
| Free cash flow | -$18.3M | -$15.1M | $20.9M | -$2.49M | -$38.6M |
| Capital expenditure | $7.80M | $4.35M | $5.18M | $5.45M | $2.71M |
| Total debt | $436M | $437M | $433M | $84.0M | $83.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | $1.44B | -7% | +13% | -7% | 2.3× | n/a |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
| Roche RO.SW | $381B | +21% | -1% | 31% | 5.7× | 1.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IMCR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.6% | -10.2% | 8th lowest of 21 |
| 6-month return | -6.9% | -20.3% | 8th highest of 20 |
| Distance from 52-week high | -32.4% | -47.0% | 3rd highest of 21 |
| Revenue growth (TTM) | +13.0% | +26.4% | 6th lowest of 17 |
| Operating margin | -6.8% | -295.1% | 7th highest of 18 |
| EV / Sales | 2.3× | 26.5× | cheapest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | 2.3× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 4.9× | 39.4% | -2.5% |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | 205.0× | n/a | n/a |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 6.3× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | n/a | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 7.9× | 0.5% | +25.6% |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | 50.1× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | 12.8× | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | 359.6× | n/a | n/a |
| CanSino Biologics 688185.SS | China | $1.38B | 0% | +30% | -4% | 6.6× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | 408.9× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | 21.3× | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | 13.1× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | 1,058.7× | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 10.1× | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | 31.7× | n/a | n/a |
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh has 1 bond outstanding with $402M face value.